Safety and Dose Finding Study of Xigris in Hemodialysis Patients

Completed · Phase 2

Conditions studied: End Stage Renal Disease

In brief

The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).

Key facts

Study ID

NCT01227187

Run by

George Washington University

People needed

12

Starts

2008-10-01

Expected to finish

2010-12-01

Last updated by the study team

2022-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >18
• Usually used heparin with HD

You may not qualify if…

• Plt <100
• Pregnancy
• H/o bleeding diathesis
• H/o CVA
• Pt on Ticlid/plavix/warfarin
• SBP >200
• BASELINE PTT>50
• INR>1.6

Where it is running

• The George Washington University Hospital — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.